Login/Register – amsonia | Pharma Middle East

Friday, January 16, 2026

Creating liberating content

AstraZeneca to Acquire EsoBiotec...

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

Signal12 gears up for...

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the...

Log In

Username or Email address

Password Forgot password?

Don't have an account? Sign up

Or continue reading...

News

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

Joseph George -

Press Releases

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

Joseph George -

Enjoy exclusive access to our content

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

Get email updates with every new article published

Get email updates with every new article published

Unlock an exclusive experience

Email based subscription

Annual subscription

Corporate subscription

Get email updates with every new article published

AstraZeneca to Acquire EsoBiotec...

Signal12 gears up for...

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

Enjoy exclusive access to our content

Unlock an exclusive experience

Email based subscription

Yearly based subscription

Monthly based subscription

Amsonia Menu

Categories to explore

Contribute as an author

Who we are

Explore the website

Get email updates with every new article published

.cls-Amsonia1{fill:#eaecf8;}.cls-Amsonia2{clip-path:url(#clip-path);}.cls-Amsonia3{fill:#6d9af8;}.cls-Amsonia4{fill:#366bd9;}

Looking for something?

Explore the website

Get email updates with every new article published

.cls-Amsonia1{fill:#eaecf8;}.cls-Amsonia2{clip-path:url(#clip-path);}.cls-Amsonia3{fill:#6d9af8;}.cls-Amsonia4{fill:#366bd9;}

Looking for something?

.cls-Amsonia1{fill:#eaecf8;}.cls-Amsonia2{clip-path:url(#clip-path);}.cls-Amsonia3{fill:#6d9af8;}.cls-Amsonia4{fill:#366bd9;}

Enjoy the benefits of exclusive reading

Unlock an exclusive experience

Email based subscription

Annual subscription

Corporate subscription

Explore the website

Get email updates with every new article published

Looking for something?

AstraZeneca to Acquire EsoBiotec...

Signal12 gears up for...

Log In

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

Enjoy exclusive access to our content

Enjoy the benefits of exclusive reading

Unlock an exclusive experience

Email based subscription

Yearly based subscription

Monthly based subscription

Amsonia Menu

Categories to explore

Contribute as an author

Who we are

.cls-Amsonia1{fill:#eaecf8;}.cls-Amsonia2{clip-path:url(#clip-path);}.cls-Amsonia3{fill:#6d9af8;}.cls-Amsonia4{fill:#366bd9;}